mcla-129
merus
['mcla-129', 'merus ']
we re excited to share new preclinical data today at #aacr23 on our clinical stage egfr and c-met bispecific antibody, mcla-129, a target combination receiving increasing attention in clinical investigation.
#closeinoncancer 
Clinical-stage oncology company developing Biclonics® bispecific antibody therapeutics. Please see our Community Guidelines: https://t.co/qN9crK04bE